B16 Melanoma Model
B16 Melanoma Model - Related Videos
03:52
Experimental Metastatic Melanoma Mouse Model: A Platform to Study the Metastatic Potential of Melanoma Cells in the Lungs
0 Views •
2023
In this video, melanoma cells are intravenously injected through the tail vein in the mouse model. The melanoma cells further travel through the circulatory system, adapting to the distant microenvironment and causing metastasis in organs like lungs.
07:31
Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs
0 Views •
Cited by 13 •
2016
Metastasis plays a profound role in the virulence of cancer, accounting for an estimated 90% of deaths. We report a protocol for a metastatic melanoma model in mice that is useful for determining the efficacy of therapeutic agents against this clinical phenomenon.
03:16
Patient-derived Xenograft Modeling: A Technique to Generate Melanoma Mouse Models
0 Views •
2023
In this video, human-derived melanoma cells are implanted subcutaneously into the flank region of an immunocompromised mouse. The PDX model allows preclinical investigation of melanoma cells that better recapitulate the tumor heterogeneity and melanoma aggressiveness observed in in vivo conditions.
10:23
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
0 Views •
Cited by 32 •
2012
A rapid way to screen for melanoma modifiers using a zebrafish autochthonous tumor model is presented. It takes advantage of the miniCoopR vector which allows for expression of candidate melanoma genes in melanocytes. A method to obtain melanoma-free survival curves, an invasion assay, a protocol for antibody staining of scale melanocytes and a melanoma transplantation assay are described.
04:05
Subcutaneous Transplantation Assay: A Method to Transplant Melanoma Cells from a Donor to a Recipient Zebrafish Model
0 Views •
2023
This video describes the method for transplantation of tumor cells from the melanoma-bearing donor zebrafish model to an immunocompromised recipient Casper zebrafish. It helps to visualize tumor engraftment and proliferation in the recipient fish.
FAQs
B16 melanoma cells and C57BL/6 mice are genetically compatible, allowing tumor growth in a host whose immune system can recognize and respond to the tumor within the same genetic background. This arrangement preserves tumor–immune interactions that would be disrupted in an incompatible host, making the model useful for examining how melanoma biology and immunity influence one another in vivo.
An immunocompetent mouse retains the immune-cell responses that can affect tumor progression and treatment outcomes. As a result, experiments can assess not only whether a tumor grows, but also how antitumor immunity changes during disease or after therapy. This feature is particularly relevant when investigating cancer treatments that depend on interactions between tumor cells and the immune system.
Tumor burden provides one measurable outcome, but the model also supports analysis of tumor progression, metastasis, and immune-cell responses. Considering these outcomes together can distinguish a treatment that broadly limits tumor growth from one that alters dissemination or stimulates antitumor immunity. Such comparisons connect cellular and molecular mechanisms with observable effects in the whole animal.
Results from this murine system require careful interpretation before being extended to human melanoma. The model reproduces selected tumor and immune interactions in a controlled, genetically compatible setting, but it does not establish that the same mechanisms or treatment effects will occur in people. Its strongest value is therefore comparative and mechanistic, helping guide questions that require further validation.
A typical workflow begins by implanting B16 melanoma cells into syngeneic C57BL/6 mice and allowing tumors to develop in an immunocompetent host. Researchers then compare tumor growth or other defined outcomes across experimental conditions, including treatment groups when appropriate. Measurements of tumor burden, metastasis, immune-cell responses, and treatment efficacy provide the basis for evaluating biological effects.
This model is useful when an experiment needs an in vivo melanoma system that preserves genetically compatible tumor–immune interactions. It can support studies of melanoma development and progression, investigations of metastasis, and testing of cancer therapies, including immunotherapies. The controlled setting also enables comparisons among tumor burden, immune responses, and treatment outcomes within whole-animal biology.
Treatment effects can be assessed by comparing tumor burden and progression between experimental groups, while also examining metastasis and immune-cell responses. These measurements help determine whether an intervention produces a broader antitumor effect or influences a particular biological outcome. Including immune-related observations is especially important for interpreting therapies whose activity depends on antitumor immune responses.